Articles published by Immunome, Inc.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2025
From Immunome, Inc.
Via Business Wire
Tickers
IMNM



Immunome Announces Proposed Public Offering of Common Stock
January 29, 2025
From Immunome, Inc.
Via Business Wire
Tickers
IMNM

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
From Immunome, Inc.
Via Business Wire
Tickers
IMNM


Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2024
From Immunome, Inc.
Via Business Wire
Tickers
IMNM


Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
November 13, 2024
From Immunome, Inc.
Via Business Wire
Tickers
IMNM


Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2024
From Immunome, Inc.
Via Business Wire
Tickers
IMNM

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
October 29, 2024
From Immunome, Inc.
Via Business Wire
Tickers
IMNM







Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
July 25, 2024
From Immunome, Inc.
Via Business Wire
Tickers
IMNM

Immunome Appoints Phil Tsai as Chief Technical Officer
June 27, 2024
From Immunome, Inc.
Via Business Wire
Tickers
IMNM







Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
March 28, 2024
From Immunome, Inc.
Via Business Wire
Tickers
IMNM

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
March 26, 2024
From Immunome, Inc.
Via Business Wire
Tickers
IMNM


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.